frog, my memory fails me? Surely not. Perhaps this is the sort of thing that you are looking for:
There is no intention of issuing 1 billion shares anytime soon. We'd be lucky to place 100 Million during the warrants plan and this would bring our issued shares to 600 Million. At that point we will have to live off of license fees from deals, product revenues and the proceeds from the 100 Million shares placed. I dont see the 1.5 billion authorized shares dictating our market cap rather than the 600 million that would be outstanding at that time, which is not that much greater than the 500 million we are at right now. The warrants plan is not a float bloating plan - remember its to existing investors not investment bankers. If we go to another strategy after the warrants plan, perhaps due to low participation, we would seek to place restricted stock in the hands of legitimate investors via a private placement.
On the other hand, if a pharmaceutical company came along to buy equity in DNAPrint, issuing restricted shares to them would increase the issued number, but we would try to have them also purchase on the open market and we believe that in such a scenario, the dilution would be likely be well worth it for the average shareholder (for several reasons).
If our stock becomes devalued prior to any of this, well change our tactics to adjust. We see enough genuine interest in DNAPrint from "big contract" companies to warrant enthusiasm for the plan we have put forth and the long term viability of the company we have built. Down sizing would be a mammoth mistake at the present time.
Getting warmer...
News 
Market Data 
Discover 
